Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy

Byung Il Yeh, Kwang Hyub Han, Seung Hee Oh, Hyon Suk Kim, Suk Hyun Hong, Sang Hwan Oh, Yoon Soo Kim

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Ten patients with hepatitis C virus (HCV) infection (experimental group) were treated with interferon-α (IF-α). Dosage was six million units per day for one week and then three times a week for another six months. Seven HCV-infected patients (control group) did not receive IF-α therapy. The hypervariable region (HVR) of HCV in the sera of patients was amplified by reverse trancription-polymerase chain reaction (RT-PCR), and the variation of amino acid sequence in this region was determined. Serum alanine aminotransferase (ALT) activities in five patients treated for six months with IF-α fell to the normal range, when HCV was not detected in the sera of three patients. The nucleotide sequence variation in HVR of HCV in the sera of five patients who responded well to the IF-α. therapy was relatively less than that in another five patients who did not respond to IF-α therapy and those in the control patients. These results indicate that the effectiveness of IF-α therapy was related to the sequence variation of HVR of HCV. This may have resulted from the selection pressure by humoral antibodies directed to HVR of HCV. It is concluded that the higher rate of sequence variation in HVR of HCV was compatible with a lower degree of effectiveness of IF-α therapy.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalJournal of Medical Virology
Volume49
Issue number2
DOIs
Publication statusPublished - 1996 Jun 1

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy'. Together they form a unique fingerprint.

  • Cite this